10-Q: Vivos Therapeutics Reports First Quarter 2024 Results Amidst Revenue Challenges and Strategic Shifts

Vivos Therapeutics experienced a decrease in revenue and a net loss in the first quarter of 2024, while also navigating strategic shifts and ongoing market challenges.

Summary

• Vivos Therapeutics reported a net loss of $3.763 million for the first quarter of 2024, compared to a net loss of $1.703 million in the same period of 2023.
• Total revenue decreased by 11% to $3.419 million, with both product and service revenue experiencing declines.
• Product revenue fell to $1.674 million, while service revenue decreased to $1.745 million.
• The company's gross profit was $1.937 million, with a gross profit margin of 57%, down from 61% in the first quarter of 2023.
• Operating expenses decreased to $5.722 million, primarily due to lower general and administrative costs.
• The company had $2.611 million in cash and cash equivalents as of March 31, 2024, which is deemed insufficient to fund operations for the next twelve months without additional financing.
• Vivos enrolled 50 new VIPs in the first quarter of 2024, compared to 36 in the same period of 2023, but recognized lower revenue per contract due to new entry levels into the VIP program.
• The company sold 1,996 oral appliance arches in the first quarter of 2024, a 6% decrease compared to the 2,369 sold in the first quarter of 2023.

Sentiment

Score: 3

Explanation: The document presents a concerning financial picture with declining revenue, increased losses, and a need for additional financing. While there are some positive developments, the overall tone is negative due to the company's financial instability and ongoing challenges.

Positives

• Operating expenses decreased by $1.6 million, primarily due to lower general and administrative costs.
• The company has increased its estimated customer life for VIPs to 27 months in 2024, indicating improved customer retention.
• The company has made progress in penetrating the DSO market, although the impact on revenue is not expected to be material in 2024.
• The company has entered into distribution agreements with third parties, including Lincare, to expand access to its products.
• The company has commenced a clinical research study with Stanford University to evaluate the efficacy of its DNA appliance.

Negatives

• The company experienced a significant increase in net loss, from $1.703 million in Q1 2023 to $3.763 million in Q1 2024.
• Total revenue decreased by 11% year-over-year, with declines in both product and service revenue.
• Gross profit margin decreased from 61% to 57% year-over-year.
• The company's cash and cash equivalents of $2.611 million are insufficient to fund operations for the next twelve months without additional financing.
• The Lincare distribution agreement has progressed slower than anticipated, and is not expected to materially impact revenue in the near term.
• The company experienced a decline in product sales revenue, which only began to reverse somewhat after the end of the first quarter of 2024.

Risks

• The company's ability to continue as a going concern is in doubt without additional financing.
• The company is subject to risks related to inflation, supply chain disruptions, and global economic uncertainty.
• The company is subject to ongoing litigation, which could have a material adverse effect on its business.
• The company is subject to the risk of Nasdaq delisting if it fails to maintain compliance with the minimum stockholders equity requirement.
• The company's revenue growth is dependent on the enrollment of new VIPs and the number of Vivos treatment case starts by existing VIPs.
• The company's business is subject to seasonal fluctuations in patient volumes.

Future Outlook

The company anticipates that it will be required to obtain additional financing to satisfy its cash needs and bolster its stockholders equity for Nasdaq compliance purposes, as management continues to work towards increasing revenue to achieve cash flow positive operations in the foreseeable future. The company is also focused on expanding its product offerings and strategic collaborations to drive revenue growth.

Management Comments

• Management is reviewing all options to obtain additional financing to fund operations.
• Management believes that the company has made important progress in penetrating the DSO market, but does not expect DSO training or product sales to materially impact overall revenue in 2024.
• Management believes that the company has made progress towards remediation and continues to implement its remediation plan for the previously reported material weakness in internal control over financial reporting.

Industry Context

The company operates in the medical technology and services sector, specifically focusing on treatments for dentofacial abnormalities and obstructive sleep apnea. The company faces competition from other medical device companies and traditional sleep apnea treatments such as CPAP. The company is also navigating challenges in the broader sleep apnea oral appliance market.

Comparison to Industry Standards

• The company's revenue decline and increased net loss in Q1 2024 are concerning when compared to industry standards for medical device companies, which typically aim for consistent revenue growth and profitability.
• The company's gross profit margin of 57% is lower than the average for medical device companies, which often have margins above 60%.
• The company's reliance on external financing to sustain operations is a significant risk, as many established medical device companies are able to fund operations through their own cash flow.
• The company's ongoing litigation and risk of Nasdaq delisting are also significant concerns that are not typical for established medical device companies.
• The company's strategic shift towards DSOs and distribution agreements is a common strategy in the medical device industry, but the company's success in these areas remains to be seen.

Legal Proceedings

• The company is involved in ongoing litigation with Ortho-Tain, Inc. in the United States District Court for the District of Colorado.
• The company is also involved in ongoing litigation with Ortho-Tain, Inc. in the United States District Court for the Northern District of Illinois.
• The company was involved in arbitration with Dr. G. Dave Singh, which has been settled.

Stakeholder Impact

• Shareholders are impacted by the company's financial instability and the risk of Nasdaq delisting.
• Employees are impacted by the company's cost-cutting measures and potential for further reductions in force.
• Customers (VIP dentists) are impacted by the company's strategic shifts and potential changes in product offerings.
• Suppliers are impacted by the company's financial instability and potential for changes in purchasing patterns.
• Creditors are impacted by the company's financial instability and potential for default on debt obligations.

Next Steps

• The company will continue to implement its remediation plan for the previously reported material weakness in internal control over financial reporting.
• The company will continue to work towards increasing revenue to achieve cash flow positive operations.
• The company will continue to explore options for additional financing.
• The company will continue to monitor the overall landscape of potential viral or other diseases which may pose a threat.
• The company will continue to monitor the overall landscape of potential viral or other diseases which may pose a threat.

Key Dates

Keywords

Vivos Therapeutics, obstructive sleep apnea, OSA, oral appliances, VIP program, revenue, net loss, financial results, medical devices, dental, healthcare, sleep apnea treatment, DNA appliance, Lincare, DSO, clinical trial